N/A N=434 VAscular Closure for Cardiac Ablation Registry (VACCAR)
Atrial Fibrillation
Primary: Hemostasis — 9; 20; 7 minutes
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=63 Surgery Followed by Risk-Directed Post-Operative Adjuvant Therapy for HPV-Related Oropharynx Squamous Cell Carcinoma: "The Minimalist Trial (MINT)"
HPV Related Oropharyngeal Squamous Cell Carcinoma
Primary: Mean Percent Weight Change — -4.89; -3.18; -10.11 percent of change
Phase 2 N=27 Safety and Efficacy Study of Vaccine Schedule With Ad26.Mos.HIV and MVA-Mosaic in Human Immunodeficiency Virus (HIV)-Infected Adults
Human Immunodeficiency Virus
Primary: Percentage of Participants With Grade 3 or 4 Solicited Local Adverse Events (AEs) — 0; 0 percentage of participants
N/A N=12,909 Universal vs. Targeted School Screening for Adolescent Major Depressive Disorder
Major Depressive Disorder · Major Depressive Episode
Primary: Major Depressive Disorder (MDD) Composite: Positive Patient Health Questionnaire-9 (PHQ-9; Universal Arm) or MDD Concern Prompting Student Assistance Program (SAP)…
N/A N=62 Iterative Beta Testing of Videos for the DIPPer Academy
Type1diabetes
Primary: Child Glycemic Control — 7.56; 8.14 percentage of glycated hemoglobin cells
N/A N=906 Philadelphia Telemedicine Glaucoma Detection and Follow-Up Study
Glaucoma · Glaucoma Suspect · Diabetic Retinopathy
Primary: Fundus Camera Images Via Telemedicine — 355; 384; 167 Participants
N/A N=123 Ranger™ and Ranger™ SL (OTW) DCB) in China
Femoropopliteal Artery Lesions
Primary: Major Adverse Events Through 30 Days Post-procedure — 121 Participants
N/A N=22 Local Heat Stress in Autonomic Failure Patients With Supine Hypertension
Hypertension · Pure Autonomic Failure · Multiple System Atrophy
Primary: Change in Systolic Blood Pressure — 19; 3 mm Hg
Phase 2 N=107 A Phase 1/2 Trial of SRA737 in Subjects With Advanced Cancer
Advanced Solid Tumors or Non-Hodgkin's Lymphoma (NHL)
Primary: Number of Subjects With Adverse Events as Assessed by CTCAE 4.03 — 106 Participants
Phase 1 N=9 A Phase 1 Study Of Talazoparib, PARP Inhibitor, In Japanese Patients With Advanced Solid Tumors
Neoplasms · Breast Neoplasms
Primary: Dose Escalation: Number of Participants With Dose-Limiting Toxicities (DLT) — 0; 0 Participants
Phase 4 N=432 Inhaled Selective Pulmonary Vasodilators for Advanced Heart Failure Therapies and Lung Transplantation Outcomes
Heart Transplant Surgery · Lung Transplant Surgery
Primary: Number of Participants With Grade 3 Primary Graft Dysfunction (PGD) for Lung Transplant Subjects — 39; 46 Participants — p=0.019
N/A N=18 Standard vs Ultrasound-assisted Catheter Thrombolysis for Submassive Pulmonary Embolism
Cardiovascular Diseases
Primary: Percentage of Thrombus Obstruction — 33; 31; 23; 22 percentage of thrombus obstruction
N/A N=6 Utility of Continuous Pulse Oximetry for Pediatric Patients With Stable Respiratory Illness
Respiratory Disease · Asthma in Children · Pneumonia in Children
Primary: Length of Stay, Measured in Days — 1.15; 1.04 days
Phase 2 N=65 Screening Trial of Nivolumab With Image Guided, Stereotactic Body Radiotherapy (SBRT) Versus Nivolumab Alone in Patients With Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
Head and Neck Squamous Cell Carcinoma (HNSCC)
Primary: Percentage of Participants With Overall Response Rate — 34.5; 29 percentage of participants
Phase 2 N=283 Study of Radium-223 Dichloride in Combination With Exemestane and Everolimus Versus Placebo in Combination With Exemestane and Everolimus in Subjects With Bone Predominant HER2 Negative Hormone Receptor Positive Metastatic Breast Cancer
Breast Neoplasms
Primary: Symptomatic Skeletal Event-free Survival (SSE-FS) — 21.1; 19.9 Months — p=0.4843